This study was undertaken to analyze the specificity and neutralizing properties of cross-reactive anti-gpl20 antibodies (Abs) in the sera of two human immunodeficiency virus (HIV)-infected asymptomatic individuals. Two panels of murine monoclonal anti-idiotype Abs (anti-id MAbs) were established against cross-reactive polyclonal anti-gpl20 Abs purified from HIV+ sera by sequential affinity chromatography using gpl20s-and gpl2OMB-Sepharose columns. These panels of anti-id MAbs were then used to affinity purify idiotype-positive (Id') anti-gpl20 Abs from HIV+ sera. The recovery of each of these Id' Abs by purification indicated that several idiotypically distinct cross-reactive anti-gpl20 Abs are present in sera over a wide range of concentrations. Immunological and biological studies showed that although all of the Id' Abs were reactive against gp120sF2 and gp120mB, they exhibited unique epitope specificities and distinct neutralizing activities. Most of the Id' Abs were directed against epitopes in the CD4 attachment site (CD4 site epitopes) of gpl20 and exhibited a spectrum of broadly neutralizing activities. On the other hand, a minor population of Id' Abs showed specificity for the V3 region of gpl20 and exhibited limited cross-neutralizing activities. Together, these studies indicate that the CD4 site epitope-specific Abs are heterogeneous with respect to their clonality, neutralizing activity, and concentration in sera. This heterogeneity suggests that anti-gpl20 Abs to the CD4 attachment site are developed in response to multiple overlapping epitopes present on the original virus isolate and/or epitopes on mutated variants which emerged over time.
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Envelope glycoprotein gpl20 of human immunodeficiency virus type 1 (HIV-1) contains several epitopes capable of inducing neutralizing antibodies (Abs) in infected individuals. The third hypervariable region (V3) of gpl20 is one such region and is known as the major neutralizing epitope (5, 14, 28, 32) . Most Abs to this region which have been elicited by either vaccination or natural infection exhibit strain-or type-specific neutralizing activity (5, 14, 18, 28, 32) . The hypervariability of the envelope region outside, as well as within, the V3 region suggests that HIV mutants that escape neutralization by V3-specific Abs emerge over time (19) .
A second significant neutralizing target of gpl20 resides in its CD4 attachment site (CD4 site epitopes). The epitopes in this site are conformationally dependent (3, 7, 30) and composed of several discontinuous regions (11, 22, 31) . Recently, we demonstrated that human Abs specific for the CD4 site epitopes, isolated from the sera of HIV-infected individuals, possess broadly neutralizing activity (10) . Several examples of human monoclonal Abs (MAbs) specific for this region have also been shown to have broadly neutralizing activity (7, 24, 33) . Moreover, functional analysis of Abs with different specificities for this region suggest a diversity in the neutralizing epitopes in this region (4, 6) .
Despite extensive studies on different neutralizing targets of gpl20, no comprehensive analysis of cross-reactive antigpl20 Abs elicited by natural infection has been reported. Isolation of anti-gp120 Abs. Cross-reactive anti-gpl20 Abs were isolated from the sera of HIV-infected individuals by affinity chromatography. Serum, inactivated by detergent (1% Nonidet P-40) and heat (1 h at 56°C), was first passed over a gpl20SF2-Sepharose 4B column. After the column was washed extensively with phosphate-buffered saline (PBS), the column-bound Ab was eluted with citrate buffer at pH 2.8 and dialyzed against PBS. The anti-gpl20SF2 Abs that cross-reacted with gp12011IB were then isolated by affinity chromatography by using a gp120,1IB-Sepharose column and conditions similar to those described above.
Development of anti-id MAbs. Anti-id MAbs specific for cross-reactive anti-gpl20 Abs were developed by methods previously described by us (4) . BALB/c mice were immunized with cross-reactive affinity-purified anti-gpl20 Abs isolated from two HIV+ sera. All Isolation of Id' Abs. Id' Abs from HIV+ sera were isolated by methods described earlier (4) . Briefly, 80 to 160 ml of the serum used for cross-reactive anti-gpl20 Ab preparations was applied to an anti-id Ab-Sepharose 4B Radiolabeled gpl20 (50,000 cpm/50 ,l per well) and various concentrations of Id' Abs were preincubated for 1 h, and the mixtures were added to the wells. At 3 h later, the plates were washed and the bound radioactivity per well was measured. Percent inhibition was calculated as [1 - (cpm with inhibitor/cpm without inhibitor)] x 100.
Neutralization assay. A quantitative neutralization assay with HIV-1 laboratory strains was performed as previously described (16, 35) . Monolayers of CEM-SS target cells were cultured with different HIV strains in the presence or absence of different neutralizing Abs, and 3 to 5 days later, numbers of syncytium-forming units were determined. An equivalent amount of virus was used in the assays to allow direct comparison of the various Ab concentrations tested. The assays were repeatable over a virus-surviving fraction range of 1 to 0.001 within a range of two-to fourfold differences in Ab concentration (P < 0.001).
RESULTS
Characterization of HIV+ sera. Sera from two HIV+ asymptomatic individuals (sera I and II) were selected for analysis of cross-reactive neutralizing anti-gpl20 Ab populations. Prior to analysis, the virus strains responsible for the seroconversion of these individuals were determined. Since the V3 region of gpl20 is specific for each HIV isolate, analysis of the humoral response to this region indicated the strain of HIV that had infected these individuals. Therefore, the sera were tested for the ability to bind to V3 regionderived peptides. As indicated in Table 1 b Anti-gpl20 Abs were isolated from either serum I or serum II by affinity purification on gpl20sF2-and gpl201IB-conjugated Sepharose columns.
c Normal Igs were prepared from anti-gp120 Ab-depleted serum I or serum II by affinity purification using protein G.
binding to SC V3 and WMJ-2 V3 peptides. This suggests that the donors of the HIV+ sera were infected with MN or an MN-like strain of HIV-1. When tested for neutralizing activity against laboratory strains MN, IIIB, and RF, both sera neutralized all three strains effectively. The neutralizing activity against MN was only slightly higher than that of the other two strains, indicating that in addition to MN V3-specific neutralizing Abs, the sera contained a substantial amount of broadly neutralizing Abs (data not shown).
Isolation of different populations of cross-reactive antigp120 Abs by anti-id MAbs. To fractionate different crossreactive anti-gpl20 Ab populations in sera, two panels of anti-id MAbs were established. Total cross-reactive antigpl20 Abs from HIV+ sera I and II were independently prepared by sequential affinity purification on two different gpl20 (IIIB and SF2)-conjugated Sepharose columns. The purified Abs were used to immunize mice for development of anti-id MAbs. The anti-id MAbs that showed specific binding to the total cross-reactive anti-gpl20 Abs but not to the anti-gpl20-depleted normal Ig fraction of the sera were selected for further analysis (Table 2) . By this criterion, 34 anti-id MAbs to serum I anti-gpl20 Abs and 19 anti-id MAbs to serum II anti-gpl20 Abs were selected for further analySiS.
To determine whether the anti-id MAbs cross-recognize the same population of anti-gpl20 Abs, the Id' Ab corresponding to each anti-id MAb was isolated from the sera by using anti-id MAb-Sepharose columns. The Id' Ab isolated by each Binding of Id+ Abs to synthetic V3 region-derived peptides was determined. As listed in Table 6 , AP+ and AD+ Abs of serum I and FD+ Ab of serum II bound to the V3 peptide, indicating that these are specific for the V3 region of gpl20.
However, the finding that binding of FD+ Ab to gp120sF2 (Fig. 1B) . In addition, when other Id' Abs were tested as described above, similar inhibitions were observed (data not shown). Overall, the J. VIROL. Fig. 2A and B) . The Id' Abs specific for the CD4 site epitopes, as well as those to the V3 region, exhibited a broad spectrum of neutralizing activities against multiple strains of HIV-1. Among the CD4 site epitope-specific Id' Abs of serum I, AC', AL', AB', and BZ+ Abs neutralized all three strains. AO' Ab neutralized MN efficiently and IIIB weakly but did not neutralize the RF strain, whereas BJ+ Ab neutralized only MN. Of the CD4 site epitope-specific Id' Abs from serum II, CP+ and DI' Abs neutralized all three strains, whereas DA' and FE' Abs neutralized only the MN and IIIB strains. All three V3-specific Id' Abs of serum I (AD' and AP' Abs) and serum II (FD+ Ab) effectively neutralized MN but did not neutralize the IIIB strain. Both AP' and FD+ Abs also neutralized the RF strain. The CX+ Ab, with unknown specificity, failed to neutralize any of the strains tested. In general, CD4 site epitope-specific Id' Abs exhibited a spectrum of broadly neutralizing activities, while V3-specific Id' Abs neutralized a single strain efficiently with limited cross-neutralizing activity ( Fig. 2A and B) . (Table 5) .
by using anti-id MAbs. A summary of the data (Table 7) indicates that most of the cross-reactive anti-gpl20 Abs are specific to the CD4 site epitopes and heterogeneous with respect to clonality, neutralizing activity, and concentration in serum. A minor population of the cross-reactive antigpl20 Abs is directed to the V3 region.
Idiotypes are ubiquitous markers of Ig variable regions which are recognized by anti-id Abs (1, 12, 13, 23, 26, 29) . Idiotopes can be unique and associated with an Ab of a given specificity (private Id) (1, 12) or shared by Abs with different specificities (cross-reactive Id) (1, 34) . On the basis of the linkage between idiotopes and epitope specificity of an Ab, we selected anti-Id MAbs that are specific to the anti-gpl20 Abs but not to Abs with unrelated specificity (normal Ig).
Such anti-id MAbs were used to isolate and characterize various populations of cross-reactive anti-gpl20 Abs elicited by natural infection. The advantages of this approach over other techniques, such as generation of human MAbs, are that (i) targeted Ab populations, such as the cross-reactive anti-gpl20 Abs, can be comprehensively analyzed with respect to their immunological and biological properties, and (ii) by determining the concentration of each Ab population (Id' Abs) in serum, the humoral response against individual epitopes accumulated over the course of infection can be estimated. The fact that the various Id' Abs isolated by this anti-id approach exhibit different epitope specificities and neutralizing activities enabled us to effectively analyze the cross-reactive anti-gp120 Ab population in HIV+ sera.
In the testing of Id' Ab binding to the V3 peptide (Table  6 ), three Id' Abs (AP', AD', and FD+) were found to be specific to the V3 region. Although these Id' Abs crossreacted with gpl20s from two strains, they showed weak binding activity to gp120111B (Tables 4 and 5 ). This low level of binding explains the inability of these Id' Abs to neutralize the IIIB strain of HIV. Among the V3-specific Id' Abs, AP' and FD+, but not AD+, neutralized the RF strain.
Furthermore, the fact that these V3-specific Id' Abs were isolated from the sera of individuals who were infected with an MN-like strain of HIV could explain the stronger neutralizing activities observed with these Id' Abs against the MN strain. Collectively, these data indicate that a subpopulation of V3-specific Abs in HIV-infected individuals cross-reacts with multiple strains of HIV, as described by ourselves (10) and others (8, 21) . However, the ability of these Abs to neutralize multiple strains of HIV is limited mainly by their lower affinity for a certain strain.
Our earlier study showed that CD4 site epitope-specific Id' Abs isolated from a pool of HIV+ sera exhibited a spectrum of neutralizing activities against multiple strains of HIV-1 (4). We attributed these differences in neutralizing activity to the existence of antigenically diverse epitopes around the CD4 attachment site of gpl20. (20, 25, 27) , it is not clear whether the various CD4 site epitopes reside in only the original infectious isolate or whether they are present in some or all of the mutationally derived isolates of that individual. In our studies, to define CD4 site epitope-specific Abs, an inhibition assay with sCD4 was employed. This assay does not distinguish the exact location of the epitopes recognized by each Ab. Hence, a cross-inhibition assay was performed which indicated that all of the CD4 site epitopes recognized by different Id' Abs coexist in the same gpl20 molecule. As suggested by others (6) and us (4) , some of the CD4 site epitopes could completely overlap the overall structure of a CD4 attachment site, whereas others could partially overlap it. If this is the case, all CD4 site epitopes are not necessarily located within the conserved structure of the CD4 attachment site. Thus, the virus may be able to undergo mutation in the CD4 site epitopes which do not influence the overall structure of the virus attachment and thereby escape neutralization. Indeed, a recent study indicated that a CD4 site epitope-specific human MAb prepared during the early stage of infection could not neutralize the mutated virus isolated at a later stage of infection of the same individual (5a). In this regard, it will be very important to find out whether any of the CD4 site epitope-specific Id' Abs can neutralize various viral mutants. This will provide crucial information on whether truly conserved neutralizing targets exist at the CD4 attachment site.
Epitope analysis of different neutralizing Id' Abs showed that six of eight Id' Abs from serum I and four of six Id'
Abs from serum II are specific for the epitopes around the CD4 attachment site. The data on the recovery of Ab purification showed that CD4 site epitope-specific Id' Abs constitute a major portion of the cross-reactive neutralizing Abs of sera I and II. These data, in conjunction with the neutralization data, suggest that most of the cross-reactive neutralizing anti-gp120 Abs in HIV-infected asymptomatic individuals are directed to the CD4 site epitopes. Since the Ab response to the CD4 attachment site is weaker than that for the V3 site early in infection (7, 17) , the dominance of the CD4 site epitope-specific Ab response in the cross-reactive Ab population seen in our study could be attributed to the accumulation of immune responses to this relatively conserved site. The response to the CD4 site epitopes would dominate over that to the rapidly mutating V3 region, and thus over time most of the broadly neutralizing activity would be directed to the CD4 site epitopes of gpl20.
Despite the diversity in the different epitopes and lower immunogenicity, the CD4 attachment site still represents an attractive target to circumvent antigenic variation. The ability of HIV to mutate in this region is potentially restricted by the requirements for attachment to target cells. Hence, it is conceivable that Abs to this region have inherently broad neutralizing activity. Moreover, because the attachment region is conformational and consists of noncontiguous residues (11, 22, 31) , the broadly neutralizing epitopes of the CD4 attachment site cannot be represented by linear peptides (2, 15) for peptide-based vaccines. In light of these constrains, anti-id Ab-based vaccines could offer an alternative approach to elicit and/or boost CD4 attachment sitespecific broadly neutralizing Abs (9) .
